Aspirin Alone is Standard; Dual Antiplatelet Therapy is NOT Routine After CABG
Aspirin monotherapy (100-325 mg daily) should be initiated within 6 hours postoperatively and continued indefinitely after CABG—this is the established standard of care. 1 Adding clopidogrel (Plavix) routinely to all post-CABG patients is not supported by current guidelines and remains controversial.
The Guideline-Based Approach
The 2011 ACC/AHA CABG guidelines establish aspirin as a Class I recommendation (meaning it should be done), but notably do not recommend routine dual antiplatelet therapy (DAPT) for all CABG patients 1. The guideline specifically addresses stopping clopidogrel before surgery (at least 5 days for elective cases) to reduce bleeding, but does not advocate for routinely restarting it postoperatively in all patients 1.
When DAPT May Be Considered (Selective Use)
While not routine, DAPT may be appropriate in specific higher-risk scenarios:
Recent acute coronary syndrome (ACS): Patients who underwent CABG in the context of unstable angina or NSTEMI may benefit, as the CURE trial showed a 20% relative risk reduction in cardiovascular death, MI, or stroke with aspirin plus clopidogrel in ACS patients (though only ~20% underwent revascularization) 2
Off-pump CABG: Meta-analysis data suggests DAPT reduced perioperative MI risk by 68% and saphenous vein graft occlusion by 55% specifically in off-pump procedures 3
High-risk anatomic features: Diffuse coronary disease, coronary endarterectomy, or bypassing previously stented vessels 4
The Evidence Reality Check
The most recent high-quality propensity-matched study (2021) found no benefit to DAPT over aspirin alone in 3,562 CABG patients, with comparable survival (5-year: 86.3% vs 87.8%) and similar rates of major adverse cardiac and cerebrovascular events (5-year: 26.7% vs 24.7%), but DAPT was associated with significantly higher postoperative transfusion rates (30.7% vs 25.4%, p=0.001) 5. This directly contradicts the theoretical benefits and challenges the routine use of DAPT.
A 2013 meta-analysis did show DAPT reduced early saphenous vein graft occlusion (RR 0.59), but this came with a trend toward increased major bleeding (RR 1.17, p=0.05) 3. The benefit appeared most pronounced in off-pump CABG specifically.
The Bleeding Trade-Off
This is the critical pitfall: While DAPT may improve graft patency in select cases, it consistently increases bleeding risk 5, 3. In routine CABG patients without specific high-risk features, this bleeding risk outweighs uncertain benefits on hard clinical outcomes like mortality.
Practical Algorithm
Start with aspirin 100-325 mg within 6 hours postoperatively for ALL patients 1
Then stratify:
- Standard CABG for stable coronary disease: Aspirin monotherapy indefinitely
- Recent ACS (within weeks) requiring CABG: Consider adding clopidogrel 75 mg daily for 12 months
- Off-pump CABG with high-risk features: Consider adding clopidogrel 75 mg daily for 12 months
- Perioperative MI or graft thrombosis concerns: Consider adding clopidogrel 75 mg daily
If DAPT is used, clopidogrel 75 mg daily is the preferred P2Y12 inhibitor, typically started on postoperative day 1 and continued for 12 months 4.
Current Practice Variation
A 2023 UK survey revealed that 91% of cardiac surgeons prescribe DAPT postoperatively, but only 38% use it for all patients—most reserve it for selective cohorts 4. This highlights the gap between guideline recommendations (aspirin alone as standard) and real-world practice patterns driven by surgeon preference and perceived patient risk.
Bottom line: Aspirin is routine and mandatory; clopidogrel is selective and risk-stratified, not routine.